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Objectives:  This multi-center study’s aim was to assess the performance of two commercially-2 
available matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-3 
TOF MS) systems in identifying a challenge collection of clinically-relevant nontuberculous 4 
mycobacteria (NTM). 5 
Methods:  NTM clinical isolates (N=244) belonging to 23 species/subspecies were identified by 6 
gene sequencing and analyzed using the Bruker Biotyper with Mycobacterial Library v5.0.0 and 7 
the bioMérieux VITEK MS with v3.0 database. 8 
Results: Using the Bruker or bioMérieux systems, 92% or 95% of NTM strains, respectively, 9 
were identified at least to the complex/group level; 62% and 57%, respectively, were identified 10 
to the highest taxonomic level. Differentiation between members of the M. abscessus, M. 11 
fortuitum, M. mucogenicum, M. avium, and M. terrae complexes/groups was problematic for 12 
both systems, as was identification of M. chelonae for the Bruker system. 13 
Conclusions:  Both systems identified most NTM isolates to the group/complex level, and many 14 





 Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-2 
TOF MS) represents a new paradigm in the analysis of microorganisms in the laboratory (1).  3 
Initially, MS instruments were used primarily in larger reference laboratories, and the 4 
identification capabilities were limited mostly to bacterial species and yeast (2-8).  However, in 5 
the last decade, the systems have become more widely utilized in routine clinical laboratories 6 
worldwide. In response, the Clinical and Laboratory Standards Institute has recently published a 7 
guidance document to assist clinical laboratories with implementation and verification of 8 
commercial MALDI-TOF MS systems (9). The range of microorganisms identifiable using 9 
commercial systems has expanded considerably to now include filamentous fungi and 10 
mycobacteria (10-15).  11 
 This study describes a multicenter study including two laboratories routinely using 12 
MALDI-TOF MS for non-tuberculous mycobacteria (NTM) identification, with each employing 13 
a different commercial MALDI-TOF MS system and database.  The laboratory at Massachusetts 14 
General Hospital (MGH) in Boston, MA used the VITEK MS IVD system with v3.0 Knowledge 15 
Base (bioMérieux, Durham, NC) and the laboratory at the Marshfield Clinic Health System 16 
(MCHS) in Marshfield, WI used the Bruker Biotyper system with RUO Mycobacteria Library 17 
v5.0.0 (Bruker Daltonics, Billerica, MA). Isolates had previously been identified by gene 18 
sequencing approaches at the University of Texas Health Science Center at Tyler (UTHSCT) 19 
Mycobacteria/Nocardia Research Laboratory, a clinical reference laboratory with expertise in 20 
identification of NTM (13, 15). The objective of this multicenter study was to establish and 21 
compare the accuracy of each MALDI-TOF MS system for the identification of NTM clinical 22 




are few head-to-head comparisons between these MALDI-TOF MS systems for NTM 1 
identification (16, 17); to our knowledge, this is the first such study that is multicenter, and the 2 
first to include both the VITEK MS IVD system with v3.0 Knowledge Base and the Bruker 3 
Biotyper system with RUO Mycobacteria Library v5.0.0 in the same study. 4 
MATERIALS AND METHODS 5 
The study was approved by the institutional review board (IRB) at MCHS and was deemed 6 
exempt from IRB oversight at MGH and the UTHSCT, in accordance with the ethical standards 7 
established by each institution.  All isolates were de-identified prior to shipment. 8 
Clinical isolates.  The isolates (n=244) included 125 rapidly growing mycobacteria (RGM) and 9 
119 slowly growing mycobacteria (SGM) species, identified previously by gene sequencing at 10 
the Mycobacteria/Nocardia Research Laboratory at the UTHSCT (Tables 1 and 2).  The isolates 11 
had been previously stored at -70°C in trypticase soy broth (Remel, Lenexa, KS) with glycerol, 12 
and were subcultured onto Middlebrook 7H10 agar plates (Remel) and shipped on 7H10 agar 13 
slants (Remel) from UTHSCT to the two sites (MGH and MCHS). 14 
Reference method for identification.  Identification of all study isolates was performed by gene 15 
sequencing at the UTHSCT.  RGM strains were identified by sequencing the 720 bp region V of 16 
the rpoB (beta subunit of RNA polymerase) gene as described by Adekambi et al. (18, 19), and 17 
for the Mycobacterium abscessus complex, the erm(41) (erythromycin ribosomal methylase) 18 
gene was also sequenced as previously described (20) to aid in the identification of subspecies.  19 
Partial 16S rRNA gene sequencing was performed on SGM strains using MicroSeq 500 rDNA 20 
PCR and sequencing kits according to the manufacturer’s instructions (Life Technologies, 21 




from RipSeq (Pathogenomix, Santa Cruz, CA).  Quality control for gene sequencing included 1 
positive control strains (Mycobacterium fortuitum ATCC 6841T for RGM and SGM for rpoβ 2 
and 16S rRNA genes respectively, and ATCC 19977T for the M. abscessus complex erm gene 3 
control).  Sterile deionized water was also included as a negative control. To help distinguish 4 
between M. marinum (strains of which were included in this study) and M. ulcerans (not 5 
included in this study), the sequence data were supplemented with phenotypic data including 6 
growth rate.  M. marinum is an intermediately growing photochromogen (5-7d) , whereas M. 7 
ulcerans is a very slowly growing nonchromogen (>4 weeks) .  Additionally, the rpoβ gene was 8 
sequenced to separate M. kansasii (strains of which were included in this study) from M. gastri 9 
(not included in this study). 10 
MALDI-TOF MS sample extraction and analysis procedures. 11 
BioMérieux VITEK MS IVD system with v3.0 Knowledge Base 12 
Extraction.  Inactivation and extraction procedures were performed using an FDA-13 
cleared reagent kit (bioMérieux, Durham, NC), according the manufacturer’s instructions. In 14 
brief, mycobacterial isolates were subcultured onto Middlebrook 7H11 plates (Remel). When 15 
growth was sufficient, a 1 µl sterile loop was used to transfer a loopful of biomass to 0.5mm 16 
Glass Bead Tubes (MoBio Laboratories, Inc., Carlsbad, CA) containing 500 µl of 70% ethanol 17 
(Sigma-Aldrich, St. Louis, MO). The tubes were then placed for 5 minutes in a bead beater 18 
(BioSpec Products, Bartlesville, OK) for mechanical disruption and allowed to incubate at room 19 
temperature for an additional 10 minutes to complete the inactivation process. Each tube was 20 
then vortexed for 10 seconds, and the suspension was transferred to a micro-centrifuge vial and 21 




dried. Each pellet was re-suspended in 10 µl of 70% formic acid (Fisher Scientific, Waltham, 1 
MA) and incubated at room temperature for five minutes. Finally, 10 µl of acetonitrile (Sigma-2 
Aldrich) was added to each vial, mixed, and centrifuged to create a pellet. One microliter of the 3 
supernatant (extract) was transferred to spots (in duplicate) on the target slide and allowed to air 4 
dry. One microliter of α-cyano-4-hydroxycinnamic acid (CHCA) matrix (VITEK MS-CHCA, 5 
bioMérieux) was then placed on each spot and allowed to dry. 6 
MALDI-TOF MS Analysis.  An Escherichia coli reference strain (ATCC 8739) was 7 
placed on control spots on each target slide for instrument calibration. Spectra for each target 8 
were obtained using a nitrogen laser at 50 shots per second for ionization and detection of 9 
proteins with a mass-to-charge ratio (m/z) between 2,000 to 20,000 Da. Samples were analyzed 10 
in duplicate, and species identification was assigned using the v3.0 FDA 510(k) cleared database.  11 
The VITEK MS system uses a “traffic light” approach to results interpretation: when a single 12 
(non-split) identification is achieved with good confidence, the single identification is displayed 13 
along with a green light; when there is low discrimination between several possible 14 
identifications (i.e., a split identification), a list of 2 to 4 possible identifications is displayed 15 
along with a yellow light; when no identification is achieved, a red light is displayed. 16 
If initial analysis yielded a low discrimination identification, or if no identification was 17 
obtained, the VITEK MS analysis was repeated once using the same protein extract.  If this did 18 
not resolve the issue, the extraction was repeated once. 19 
Bruker MALDI Biotyper 3.3.1.0 with RUO Mycobacteria Library v5.0.0 20 
Extraction.  Heat inactivation and extraction procedures were performed according the 21 




7H11 plates (Remel). When growth was sufficient, a 1 µl sterile loop was used to transfer a 1 
loopful of biomass to 1.5 mL Safe Lock microtubes (Eppendorf, Hauppauge, NY) containing 2 
HPLC-grade water (Sigma-Aldrich, St. Louis, MO) and heated to 100°C for 30 minutes in a heat 3 
block.  After cooling absolute ethanol (Sigma-Aldrich) was added to the biomass, vortexed and 4 
centrifuged to create a pellet.  All of the residual ethanol was removed, and the pellet allowed to 5 
dry completely at room temperature.  Once dried, a small spatula tip of 0.5mm Zirconia / Silica 6 
beads (BioSpec Products, Bartlesville, OK) was added to each tube followed by 10-50 µl 7 
acetonitrile (Sigma-Aldrich), based on pellet size, and vortexed for 1 minute.  After pellet 8 
disruption, equal parts 70% formic acid (Sigma-Aldrich) were added, vortexed briefly and 9 
centrifuged to re-pellet. One microliter of the supernatant (extract) was transferred to spots (in 10 
duplicate) on a MALDI target plate (Bruker Daltonik GmbH, Bremen, Germany) and allowed to 11 
air dry. One microliter of Matrix HCCA (Bruker Daltonik GmbH) was then placed on each spot 12 
and allowed to air dry. 13 
MALDI-TOF MS Analysis.  A Bacterial Test Standard (typical Escherichia coli DH5 14 
alpha; Bruker Daltonik GmbH) was placed on control spots on each MALDI target plate for 15 
instrument calibration. Spectra for each target were obtained using a nitrogen laser at 40 shots 16 
per second (to total 240 shots) for ionization and detection of proteins with a mass-to-charge 17 
ratio (m/z) between 2,000 to 20,000 Da. Samples were analyzed in duplicate, and microorganism 18 
identification and confidence-level classification (Table 1) were assigned using the Mycobacteria 19 
Library v5.0.0 database. For each analysis, the system provides a list of possible identifications, 20 
in order of likelihood (with the highest probability identification listed first). Each possible 21 
identification is assigned a confidence score as follows: 22 




1.60 to 1.79: Low-confidence identification 1 
0.00 to 1.59: No organism identification possible 2 
Statistical Analysis. Comparisons were made using McNemar’s test. P values were 2-tailed and 3 
a value of <0.05 was considered significant. All analyses were conducted using GraphPad 4 
QuickCalcs (GraphPad Software Inc., La Jolla, CA, USA). 5 
RESULTS 6 
Overall performance in the identification of NTM clinical isolates using MALDI-TOF 7 
MS was comparable between the Bruker Biotyper and bioMérieux VITEK systems. The systems 8 
identified 92% (225/244) and 95% (231/244) of all isolates to at least the complex/group level, 9 
respectively (P=0.18; Tables 1 and 2). The Biotyper system identified 151/244 isolates (62%) to 10 
the highest taxonomic level, either the species or subspecies level depending on the organism. 11 
The VITEK system identified 138/244 of all isolates (57%) to the highest taxonomic level 12 
(P=0.11). The Biotyper system could not identify 12/244 isolates (5%) and misidentified 7/244 13 
isolates (3%); the VITEK system could not identify 11/244 isolates (5%; P=1.0) and 14 
misidentified 2/244 isolates (1%; P=0.18). The chief limitations of each system—many of which 15 
are common to both—are illustrated in Figure 1. 16 
Among RGM, the Biotyper system identified 59/125 isolates (47%) to the highest 17 
taxonomic level, and the VITEK system identified 39/125 isolates (31%) to that level (P=0.004); 18 
Table 1). The Biotyper system could not identify 3/125 RGM isolates (2%) and misidentified 19 
7/125 RGM isolates (6%); the VITEK system did not fail to identify any RGM isolates (0%; 20 
P=0.2) and misidentified 1/125 isolates (1%; P=0.08). Neither system could differentiate among 21 




M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii isolates as M. abscessus. 1 
Similarly, the Biotyper system identified 13/13 M. mucogenicum group members (5 M. 2 
mucogenicum and 8 M. phocaicum) as M. mucogenicum/phocaicum group; the VITEK system 3 
identified 5/5 M. mucogenicum isolates as M. mucogenicum, but also identified 8/8 M. 4 
phocaicum isolates as M. mucogenicum. 5 
The VITEK system reported 39/39 M. fortuitum group isolates as M. fortuitum group, 6 
whereas the Biotyper system was better able to differentiate among M. fortuitum group members. 7 
The Biotyper system identified 20/20 M. fortuitum subsp. fortuitum isolates as M. fortuitum, 9/10 8 
M. porcinum isolates as M. porcinum, 1/1 M. neworleansense isolates as M. neworleansense, and 9 
1/8 M. senegalense/conceptionense isolates as M. senegalense (M. senegalense and M. 10 
conceptionense are indistinguishable based on genomic sequencing) (21). However, the Biotyper 11 
system misidentified 1/10 M. porcinum isolates as M. abscessus, and identified 7/8 M. 12 
senegalense isolates as M. fortuitum complex. 13 
The Biotyper system misidentified 6/15 M. chelonae isolates as M. salmoniphilum, and 14 
an additional isolate (1/15) gave a split identification (M. chelonae/salmoniphilum); the 15 
remaining 8/15 isolates were identified as M. chelonae. In contrast, the VITEK system identified 16 
all 15 isolates as M. chelonae, the highest taxonomic level. The difference in the number of M. 17 
chelonae misidentifications between the 2 systems (6/15 for the Bioptyper system compared with 18 
0/15 for the VITEK system) was statistically significant (P=0.04). Both systems reported 11/11 19 
M. mageritense isolates as M. mageritense. The Biotyper and VITEK systems reported 9/9 and 20 
8/9 M. immunogenum isolates as M. immunogenum, respectively. The remaining M. 21 




Among SGM, the Biotyper system identified 92/119 isolates (77%) to the highest 1 
taxonomic level, and the VITEK system identified 99/119 isolates (83%) to that level (P=0.07; 2 
Table 2). The Biotyper system could not identify 9/119 SGM isolates (8%) and did not 3 
misidentify any SGM isolates (0%); the VITEK system could not identify 11/119 of SGM 4 
isolates (9%; P=0.5) and misidentified 1/119 isolates (1%; P=1.0). Both systems identified nearly 5 
all strains of several species to the highest taxonomic level, including M. simiae (16/16 strains on 6 
both systems), M. arupense (20/20 strains on the Biotyper system; 19/20 strains on the VITEK 7 
system, with 1 strain not identified), M. kansasii (9/9 strains on both systems), M. xenopi (9/9 8 
strains on both systems), M. nebraskense (10/10 strains on the Biotyper system; 9/10 strains on 9 
the VITEK system, with 1 strain not identified), and M. marinum (8/8 strains on both systems). 10 
Both systems also identified most M. gordonae strains to the highest taxonomic level, but the 11 
Biotyper system produced 3/14 low confidence identifications, and 3/14 strains were not 12 
identified by the VITEK system. 13 
Neither system could reliably identify M. terrae isolates. The Biotyper system identified 14 
1/7 strains to the complex level as M. terrae complex; 6/7 isolates were not identified or 15 
produced a low confidence identification. The VITEK system produced no identification for 6/7 16 
M. terrae strains, and misidentified 1/7 strains as Cronobacter malonaticus, which is not a 17 
Mycobacterium species but rather a gram-negative bacillus in the family Enterobacteriaceae. 18 
Some members of the M. avium complex (MAC) also presented difficulties. Whereas both 19 
systems identified 9/9 M. avium strains to the highest taxonomic level, and the VITEK system 20 
identified 9/9 M. intracellulare isolates to that level, the Biotyper system identified 9/9 M. 21 




Biotyper identified 8/8 M. chimaera strains as M. chimaera/intracellulare, and the VITEK 1 
system identified 8/8 M. chimaera strains as M. intracellulare. 2 
DISCUSSION 3 
The use of MALDI-TOF MS has increasingly shifted the paradigm for the identification 4 
of microorganisms in the clinical laboratory from the limited capabilities of biochemical testing 5 
to a proteomic approach with expanded capabilities. MALDI-TOF MS systems were not widely 6 
available commercially until the latter 1990s (22-24), and only cleared for routine clinical use by 7 
the FDA in 2013.  Currently, two commercial MALDI-TOF MS systems, the Bruker Biotyper 8 
and the bioMérieux VITEK MS, are being used in U.S. clinical laboratories for the identification 9 
of microorganisms, including NTM (13, 14). 10 
 The current study showed comparable results between the two commercial MALDI-TOF 11 
MS systems for NTM identification, consistent with a recent meta-analysis (25).  Although the 12 
systems identified 92% (Biotyper) or 95% (VITEK) of all isolates to at least the complex/group 13 
level, they only identified 62% or 57% of strains, respectively, to the highest taxonomic level 14 
(species or subspecies, rather than complex or group). 15 
The Biotyper system with Mycobacteria library v5.0.0 identified significantly more RGM 16 
isolates to the highest taxonomic level, compared with the VITEK v3.0 system (47% versus 17 
31%; P=0.004). Neither system could reliably differentiate among members of the M. abscessus 18 
complex or the M. mucogenicum group. In addition, the VITEK system could not differentiate 19 
among M. fortuitum group members, and the Biotyper system misidentified nearly half of M. 20 
chelonae isolates. These findings are consistent with the findings of previous studies using the 21 
VITEK v3.0 system (17, 26) or earlier versions of the Biotyper Mycobacteria library (11, 12, 17, 22 




identifying M. chelonae was described as yielding low-confidence identification scores rather 1 
than misidentifications. Also, in some other studies this limitation was not observed (29-31).  2 
Notably, in contrast to commercial (500 bp) 16S gene sequencing, both MALDI-TOF MS 3 
systems were able to differentiate the M. abscessus complex from M. chelonae, an important 4 
advantage.   5 
For SGM, the trend was reversed, although the differences did not quite meet the 6 
threshold for statistical significance: the Biotyper system identified 77% to the highest 7 
taxonomic level, versus 83% for the VITEK system (P=0.07). Neither system could reliably 8 
differentiate among members of the M. avium complex, and neither could reliably identify M. 9 
terrae isolates. These limitations in SGM identification have also been noted in studies using 10 
earlier versions of the Biotyper Mycobacteria library (16, 17, 32), and in studies using the 11 
VITEK MS v3.0 system (17). 12 
For some NTM species/groups (e.g., the M. mucogenicum group), the inability to 13 
distinguish among the members may not be clinically significant, because group members have 14 
similar antimicrobial susceptibility profiles, and public health implications (33). However, the 15 
situation is different for the M. abscessus and M. avium complexes, and the M. fortuitum group.  16 
Among M. abscessus complex members, M. abscessus subsp. massiliense strains typically lack a 17 
functional erm(41) gene, and are susceptible to macrolides, whereas M. abscessus subsp. bolletii 18 
and subsp. abscessus strains typically contain a functional erm(41) gene and are macrolide-19 
resistant (34). Thus, a laboratory report of M. abscessus complex, which would be necessitated 20 
using either MALDI MS system, would not provide all the information to guide initial therapy 21 




Similarly, members of the M. fortuitum group are responsible for variable types of 1 
clinical disease, most of which, unlike the M. abscessus complex, are treated with oral 2 
antimicrobials such as quinolones, macrolides and tetracyclines.  Some species within the M. 3 
fortuitum (e.g., M. senegalense, M. peregrinum) lack a functional erm gene and show macrolide 4 
susceptibility unlike other members (i.e., M. porcinum and other former third biovariant species), 5 
which harbor a functional erm gene rendering them inducibly macrolide resistant.  Additionally, 6 
members of the M. fortuitum group differ in resistance to quinolones and tetracyclines (33, 35-7 
38). 8 
With MAC, the member species do have similar antimicrobial susceptibility profiles, so a 9 
laboratory report of M. avium complex should not be an impediment to optimal initial drug 10 
selection. However, one particular member—M. chimaera—has been linked to nosocomial 11 
outbreaks traced to heater-cooler units used during cardiothoracic surgery (39). Thus, prompt 12 
recognition of this species from non-respiratory sites such as blood, or heart valves (tissue), may 13 
help identify outbreaks, and the inability to differentiate this species from other MAC members 14 
is a limitation with potential infection control consequences.  15 
One option to mitigate these limitations would be to use the MALDI-TOF MS 16 
identification as an initial step, with subsequent augmentation using gene sequencing in 17 
situations where further identification of an isolate is needed.  For M. abscessus complex 18 
isolates, this should include sequencing of the erm(41) gene as recommended by CLSI (40). 19 
Previously, investigators have recommended supplementation of the commercial databases with 20 
an in-house database, and this may be a viable approach in some settings, but requires extensive 21 
characterization of a large number of isolates, which is often cost- and time-prohibitive in 22 




data processing algorithms have the potential to improve performance in identifying closely-1 
related species or subspecies to the highest taxonomic level (42-46), and it may be possible for 2 
manufacturers to make such improvements in future system upgrades. 3 
Each MALDI-TOF MS system misidentified a small number of isolates (7/244 (3%) for 4 
the Biotyper system, 2/244 (1%) for the VITEK system). The difference between the two 5 
systems, in number of misidentifications, was not statistically significant. Interestingly, none of 6 
the 244 NTM strains included in this study was misidentified on both systems. The most frequent 7 
errors were the misidentification of 6/15 M. chelonae isolates as M. salmoniphilum using the 8 
Biotyper system. This is of concern because by gene sequence, the two species are easily 9 
separated (i.e., their full 16S rRNA gene sequences differ by 5 bp, their rpoB gene sequences 10 
differ by 22 bp, and their hsp65 gene sequences differ by 18 bp), and because M. salmoniphilum, 11 
unlike M. chelonae, has not been associated with human disease. This problem was not apparent 12 
with the VITEK platform, which reliably identified M. chelonae. The remaining few 13 
misidentifications on either system involved a single strain of a given species. 14 
Each system also failed to identify (or provided only a low-confidence identification for) 15 
a small number of strains (12/244 (5%) for the Biotyper system, 11/244 (5%) for the VITEK 16 
system).  Here, there was some overlap between the 2 systems. The VITEK system failed to 17 
identify 6/7 M. terrae strains and misidentified the remaining strain; the Biotyper also failed to 18 
identify 6/7 M. terrae strains. This species is not present in the VITEK v3.0 database but is 19 
represented (as M. terrae complex) in the Biotyper Mycobacteria library v5.0.0, which did 20 
identify 1/7 strains to the complex level.  Species in the M. terrae complex (M. virginiense, M. 21 
arupense, M. heraklionense, M. kumamotonense) are causative agents of tenosynovitis and thus 22 




Both systems also failed to identify 3/14 M. gordonae strains (the same 3 strains), even 1 
though this species is present in both databases.  Presumably, the databases lack sufficient strain 2 
diversity for this species.  Regarding identification of M. gordonae isolates, it is important to 3 
identify non-pathogenic species as well as pathogens in order to prevent unnecessary treatment. 4 
 There are some important limitations to our study, including the limited number of 5 
isolates tested for some species. Additionally, no species within the M. avium complex other than 6 
M. avium, M. intracellulare, and M. chimaera were included, and no species within the M. terrae 7 
complex other than M. terrae and M. arupense were tested. Finally, although differences in the 8 
ability to identify certain nontuberculous mycobacteria were observed between the Bruker and 9 
bioMérieux MALDI-TOF MS systems, the reason for these differences cannot be determined. 10 
Numerous factors known to affect performance vary between the two systems, including the 11 
approach to sample preparation, sample analysis, data analysis, and the spectral databases 12 
themselves, among many other variables.  13 
 In summary, our multicenter study is corroborative of other recent studies of NTM 14 
identification using each system individually, and also with two single-center studies comparing 15 
the two commercial platforms (12-17).  Our findings demonstrate that both the Bruker Biotyper 16 
system with RUO Mycobacterial Library v5.0.0, and the bioMérieux VITEK MS system with 17 
v3.0 database, are useful for the identification of many NTM species, but that supplemental 18 
testing would be required (if clinically indicated) to identify some mycobacteria to the highest 19 
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Table 1.  Rapidly growing mycobacteria. 
No., number. ID, identification. MisID, misidentified. 
a. To be listed in these columns, the top choice (most likely) identification was required to be high confidence (score 1.80) and non-split (Bruker system); or the result 





reference ID at 
highest taxonomic 
level (species or 
subspecies)a 
ID matches reference 
ID at group/complex 
level onlya No ID or low confidenceb ID Misidentification 
Summary of misidentifications and other explanatory 
information 
  Biotyper VITEK Biotyper VITEK Biotyper VITEK Biotyper VITEK  




3 0 7 1  
M. abscessus complex 38         No differentiation of subspecies by either Biotyper or 
VITEK 




21 1 0 0 0 ID as M. abscessus (both Biotyper and VITEK) 




12 1 0 0 0 ID as M. abscessus (both Biotyper and VITEK) 




5 0 0 0 0 ID as M. abscessus (both Biotyper and VITEK) 
M. chelonae 15 8 15 
P=0.02 
-- -- 1 0 6 0 
P=0.04 
Biotyper MisID 6/15 as M. salmoniphilum  
Biotyper ID 1/15 as M. chelonae/ salmoniphilum 
M. fortuitum group 39         No differentiation of subspecies by VITEK 
 M. fortuitum subsp. fortuitum 20 20 -- -- 20 0 0 0 0 VITEK ID 20/20 as M. fortuitum group 
 M. neworleansense 1 1 -- -- 1 0 0 0 0 VITEK ID 1/1 M. fortuitum group 
 M. porcinum 10 9 -- -- 10 0 0 1 0 Biotyper MisID 1/10 as M. abscessus 
VITEK ID 10/10 as M. fortuitum group 






8 0 0 0 0 Biotyper ID 7/8 as M. fortuitum complex 
VITEK ID 8/8 as M. fortuitum group 
M. immunogenum 9 9 8 -- -- 0 0 0 1 VITEK MisID 1/9 as M. abscessus 
M. mageritense 11 11 11 -- -- 0 0 0 0  
M. mucogenicum group 13          
 M. mucogenicum 5 -- 5 5 -- 0 0 0 0 Biotyper ID 5/5 as M. mucogenicum/phocaicum group 
  M. phocaicum 8 -- -- 8 8 0 0 0 0 Biotyper ID 8/8 as M. mucogenicum/phocaicum group 




b. A low confidence identification means the top choice identification had a low confidence score of 1.60 to 1.79 or a split identification (Bruker system); or multiple 
possible identifications were provided with a yellow light (bioMérieux system). 




Table 2.  Slowly growing nontuberculous mycobacteria. 
 
No., number. ID, identification. MisID, misidentified. 
a. To be listed in these columns, the top choice (most likely) identification was required to be high confidence (score 1.80) and non-split (Bruker system); or the result 
was required to be a single (non-split), good confidence (green light) identification (bioMérieux system). 
b. A low confidence identification means the top choice identification had a low confidence score of 1.60 to 1.79 or a split identification (Bruker system); or multiple 
possible identifications were provided with a yellow light (bioMérieux system). 




ID matches reference ID at 
highest taxonomic level 
(species or subspecies)a 
ID matches reference ID 
at group/complex level 
onlya No ID or low confidenceb ID Misidentification 
Summary of misidentifications and other 
explanatory information 
  Biotyper VITEK Biotyper VITEK Biotyper VITEK Biotyper VITEK  
Slowly growing mycobacteria 119 92 99 18 8 
P=0.004c 
9 11 0 1  
M. avium complex 26          
 M. avium 9 9 9 -- -- 0 0 0 0  
 M. chimaera 8 -- -- 8 8 0 0 0 0 Biotyper ID 8/8 as M. chimaera/intracellulare 
group 
VITEK ID 8/8 as M. intracellulare 
 M. intracellulare 9 -- 9 9 -- 0 0 0 0 Biotyper ID 9/9 as M. chimaera/intracellulare 
group 
M. gordonae 14 11 11 -- -- 3 3 0 0  
M. kansasii 9 9 9 -- -- 0 0 0 0  
M. marinum 8 8 8 -- -- 0 0 0 0 Gene sequence ID is M. marinum/ulcerans but 
growth rate excludes M. ulcerans 
1 isolate was most closely related to M. 
nebraskense by 16S rRNA gene sequence 
M. nebraskense 10 10 9 -- -- 0 1 0 0  
M. simiae 16 16 16 -- -- 0 0 0 0  
M. terrae complex 27          
 M. terrae 7 -- -- 1 -- 6 6 0 1 Biotyper ID 1/7 as M. terrae complex 
VITEK MisID 1/7 as Cronobacter malonaticus 
 M. arupense 20 20 19 -- -- 0 1 0 0  
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Figure 1. Chief limitations of the Bruker Biotyper system with RUO Mycobacteria Library 
v5.0.0 and the VITEK MS IVD system with v3.0 Knowledge Base, for the identification 
of nontuberculous mycobacteria. 
 
 
 
